Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease
Background Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist...
Gespeichert in:
| Veröffentlicht in: | BMC geriatrics 2020-10, Vol.20 (1), p.407-11, Article 407 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 407 |
| container_title | BMC geriatrics |
| container_volume | 20 |
| creator | Park, Joo-Hyun Lee, Jessie Yu, Su-Yeon Jung, Jin-Hyung Han, Kyungdo Kim, Do-Hoon Rhee, Jinnie |
| description | Background Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI. Methods A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients >= 50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use. The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72). Results The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (Pfor trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32-1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26-1.50). Conclusions The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for >= 1 year and regularly in the recent 1 year. |
| doi_str_mv | 10.1186/s12877-020-01794-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000582231800003CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_266d4d43e509415380a1dbe7673811db</doaj_id><sourcerecordid>2451835720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-576b1658b1f1dc90d62ce4ed3cdc8ca2309e4aa946327975c1271b507dd12bd23</originalsourceid><addsrcrecordid>eNqNks9u1DAQxiMEoqXwAhyQJY4Q8J_YTjggoaWUikpICM6WYzu7bhM7tR2qvicPxGx3WbU3Th57vvl57Pmq6iXB7whpxftMaCtljSmuMZFdU7NH1TFpJKkpI-3je_FR9SznSwyqloqn1RFjmHeCiuPqzypOs04-rNGcYokBzcs0Ix82vvclpoxufNmgjc9FTz7UFCVn3AwZ1I_RXDlQJLfWyW4RZeNQ8vkKxQHFXFycI0C9QUPSpizJ5Q9Io-AgZZHR2dUmhpLiiHJZ7O22bIrJAUcHxDh-izFG3-AEtrMu3oWyb-js9MdnpINFMzQDFyyjcQlZnx1Qn1dPBj1m92K_nlS_vpz-XH2tL76fna8-XdSm6USpuRQ9EbztyUCs6bAV1LjGWWasaY2mDHeu0bprBKOyk9wQKknPsbSW0N5SdlKd77g26ks1Jz_pdKui9uruIKa10gm6G52iQtjGNsxx3DWEsxZrYnsnhWQtgQhYH3eseeknZw08NenxAfRhJviNWsffSnLBGesA8HoPSPF6gS9Wl3FJAd6vaMNJy7ikGFR0pzIp5pzccLiBYLV1ldq5SoGr1J2rFIOiV_d7O5T8sxEI2p3gxvVxyAYGZdxBBkPkLd36ECLMVr7AKGNYxSUUKH3z_6XsL82t7Lw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451835720</pqid></control><display><type>article</type><title>Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><source>Web of Science - Social Sciences Citation Index – 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Springer Nature OA/Free Journals</source><creator>Park, Joo-Hyun ; Lee, Jessie ; Yu, Su-Yeon ; Jung, Jin-Hyung ; Han, Kyungdo ; Kim, Do-Hoon ; Rhee, Jinnie</creator><creatorcontrib>Park, Joo-Hyun ; Lee, Jessie ; Yu, Su-Yeon ; Jung, Jin-Hyung ; Han, Kyungdo ; Kim, Do-Hoon ; Rhee, Jinnie</creatorcontrib><description>Background Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI. Methods A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients >= 50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use. The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72). Results The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (Pfor trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32-1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26-1.50). Conclusions The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for >= 1 year and regularly in the recent 1 year.</description><identifier>ISSN: 1471-2318</identifier><identifier>EISSN: 1471-2318</identifier><identifier>DOI: 10.1186/s12877-020-01794-3</identifier><identifier>PMID: 33059626</identifier><language>eng</language><publisher>LONDON: Springer Nature</publisher><subject><![CDATA[Age ; Aged ; Aged, 80 and over ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - adverse effects ; Bisphosphonates ; Body mass index ; Case-Control Studies ; Enzyme Inhibitors - administration & dosage ; Enzyme Inhibitors - adverse effects ; Exercise ; Female ; Fracture ; Fractures ; Gastroesophageal reflux ; Gastroesophageal Reflux - drug therapy ; Gastroesophageal Reflux - epidemiology ; Gastroesophageal reflux disease ; Geriatrics ; Geriatrics & Gerontology ; Gerontology ; Histamine H2 Antagonists - administration & dosage ; Histamine H2 Antagonists - adverse effects ; Histamine H2 receptors ; Hormone replacement therapy ; Humans ; Life Sciences & Biomedicine ; Male ; Medical screening ; Older people ; Osteoporosis ; Osteoporotic Fractures - chemically induced ; Osteoporotic Fractures - epidemiology ; Peptic Ulcer - drug therapy ; Peptic Ulcer - epidemiology ; Peptic ulcer disease ; Peptic ulcers ; Physical fitness ; Population Surveillance ; Prescription drugs ; Proton pump inhibitors ; Proton Pump Inhibitors - administration & dosage ; Proton Pump Inhibitors - adverse effects ; Proton-pump inhibitor ; Republic of Korea - epidemiology ; Risk factors ; Science & Technology ; Sex ratio ; Treatment Outcome ; Ulcers]]></subject><ispartof>BMC geriatrics, 2020-10, Vol.20 (1), p.407-11, Article 407</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>16</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000582231800003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c496t-576b1658b1f1dc90d62ce4ed3cdc8ca2309e4aa946327975c1271b507dd12bd23</citedby><cites>FETCH-LOGICAL-c496t-576b1658b1f1dc90d62ce4ed3cdc8ca2309e4aa946327975c1271b507dd12bd23</cites><orcidid>0000-0002-4358-4208 ; 0000-0001-5488-5068 ; 0000-0001-7421-4501</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565339/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565339/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27929,27930,28253,28254,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33059626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Joo-Hyun</creatorcontrib><creatorcontrib>Lee, Jessie</creatorcontrib><creatorcontrib>Yu, Su-Yeon</creatorcontrib><creatorcontrib>Jung, Jin-Hyung</creatorcontrib><creatorcontrib>Han, Kyungdo</creatorcontrib><creatorcontrib>Kim, Do-Hoon</creatorcontrib><creatorcontrib>Rhee, Jinnie</creatorcontrib><title>Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease</title><title>BMC geriatrics</title><addtitle>BMC GERIATR</addtitle><addtitle>BMC Geriatr</addtitle><description>Background Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI. Methods A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients >= 50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use. The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72). Results The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (Pfor trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32-1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26-1.50). Conclusions The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for >= 1 year and regularly in the recent 1 year.</description><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - adverse effects</subject><subject>Bisphosphonates</subject><subject>Body mass index</subject><subject>Case-Control Studies</subject><subject>Enzyme Inhibitors - administration & dosage</subject><subject>Enzyme Inhibitors - adverse effects</subject><subject>Exercise</subject><subject>Female</subject><subject>Fracture</subject><subject>Fractures</subject><subject>Gastroesophageal reflux</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Gastroesophageal Reflux - epidemiology</subject><subject>Gastroesophageal reflux disease</subject><subject>Geriatrics</subject><subject>Geriatrics & Gerontology</subject><subject>Gerontology</subject><subject>Histamine H2 Antagonists - administration & dosage</subject><subject>Histamine H2 Antagonists - adverse effects</subject><subject>Histamine H2 receptors</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medical screening</subject><subject>Older people</subject><subject>Osteoporosis</subject><subject>Osteoporotic Fractures - chemically induced</subject><subject>Osteoporotic Fractures - epidemiology</subject><subject>Peptic Ulcer - drug therapy</subject><subject>Peptic Ulcer - epidemiology</subject><subject>Peptic ulcer disease</subject><subject>Peptic ulcers</subject><subject>Physical fitness</subject><subject>Population Surveillance</subject><subject>Prescription drugs</subject><subject>Proton pump inhibitors</subject><subject>Proton Pump Inhibitors - administration & dosage</subject><subject>Proton Pump Inhibitors - adverse effects</subject><subject>Proton-pump inhibitor</subject><subject>Republic of Korea - epidemiology</subject><subject>Risk factors</subject><subject>Science & Technology</subject><subject>Sex ratio</subject><subject>Treatment Outcome</subject><subject>Ulcers</subject><issn>1471-2318</issn><issn>1471-2318</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>ARHDP</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNks9u1DAQxiMEoqXwAhyQJY4Q8J_YTjggoaWUikpICM6WYzu7bhM7tR2qvicPxGx3WbU3Th57vvl57Pmq6iXB7whpxftMaCtljSmuMZFdU7NH1TFpJKkpI-3je_FR9SznSwyqloqn1RFjmHeCiuPqzypOs04-rNGcYokBzcs0Ix82vvclpoxufNmgjc9FTz7UFCVn3AwZ1I_RXDlQJLfWyW4RZeNQ8vkKxQHFXFycI0C9QUPSpizJ5Q9Io-AgZZHR2dUmhpLiiHJZ7O22bIrJAUcHxDh-izFG3-AEtrMu3oWyb-js9MdnpINFMzQDFyyjcQlZnx1Qn1dPBj1m92K_nlS_vpz-XH2tL76fna8-XdSm6USpuRQ9EbztyUCs6bAV1LjGWWasaY2mDHeu0bprBKOyk9wQKknPsbSW0N5SdlKd77g26ks1Jz_pdKui9uruIKa10gm6G52iQtjGNsxx3DWEsxZrYnsnhWQtgQhYH3eseeknZw08NenxAfRhJviNWsffSnLBGesA8HoPSPF6gS9Wl3FJAd6vaMNJy7ikGFR0pzIp5pzccLiBYLV1ldq5SoGr1J2rFIOiV_d7O5T8sxEI2p3gxvVxyAYGZdxBBkPkLd36ECLMVr7AKGNYxSUUKH3z_6XsL82t7Lw</recordid><startdate>20201015</startdate><enddate>20201015</enddate><creator>Park, Joo-Hyun</creator><creator>Lee, Jessie</creator><creator>Yu, Su-Yeon</creator><creator>Jung, Jin-Hyung</creator><creator>Han, Kyungdo</creator><creator>Kim, Do-Hoon</creator><creator>Rhee, Jinnie</creator><general>Springer Nature</general><general>BioMed Central</general><general>BMC</general><scope>17B</scope><scope>AOWDO</scope><scope>ARHDP</scope><scope>BLEPL</scope><scope>DTL</scope><scope>DVR</scope><scope>EGQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4358-4208</orcidid><orcidid>https://orcid.org/0000-0001-5488-5068</orcidid><orcidid>https://orcid.org/0000-0001-7421-4501</orcidid></search><sort><creationdate>20201015</creationdate><title>Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease</title><author>Park, Joo-Hyun ; Lee, Jessie ; Yu, Su-Yeon ; Jung, Jin-Hyung ; Han, Kyungdo ; Kim, Do-Hoon ; Rhee, Jinnie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-576b1658b1f1dc90d62ce4ed3cdc8ca2309e4aa946327975c1271b507dd12bd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - adverse effects</topic><topic>Bisphosphonates</topic><topic>Body mass index</topic><topic>Case-Control Studies</topic><topic>Enzyme Inhibitors - administration & dosage</topic><topic>Enzyme Inhibitors - adverse effects</topic><topic>Exercise</topic><topic>Female</topic><topic>Fracture</topic><topic>Fractures</topic><topic>Gastroesophageal reflux</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Gastroesophageal Reflux - epidemiology</topic><topic>Gastroesophageal reflux disease</topic><topic>Geriatrics</topic><topic>Geriatrics & Gerontology</topic><topic>Gerontology</topic><topic>Histamine H2 Antagonists - administration & dosage</topic><topic>Histamine H2 Antagonists - adverse effects</topic><topic>Histamine H2 receptors</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medical screening</topic><topic>Older people</topic><topic>Osteoporosis</topic><topic>Osteoporotic Fractures - chemically induced</topic><topic>Osteoporotic Fractures - epidemiology</topic><topic>Peptic Ulcer - drug therapy</topic><topic>Peptic Ulcer - epidemiology</topic><topic>Peptic ulcer disease</topic><topic>Peptic ulcers</topic><topic>Physical fitness</topic><topic>Population Surveillance</topic><topic>Prescription drugs</topic><topic>Proton pump inhibitors</topic><topic>Proton Pump Inhibitors - administration & dosage</topic><topic>Proton Pump Inhibitors - adverse effects</topic><topic>Proton-pump inhibitor</topic><topic>Republic of Korea - epidemiology</topic><topic>Risk factors</topic><topic>Science & Technology</topic><topic>Sex ratio</topic><topic>Treatment Outcome</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Joo-Hyun</creatorcontrib><creatorcontrib>Lee, Jessie</creatorcontrib><creatorcontrib>Yu, Su-Yeon</creatorcontrib><creatorcontrib>Jung, Jin-Hyung</creatorcontrib><creatorcontrib>Han, Kyungdo</creatorcontrib><creatorcontrib>Kim, Do-Hoon</creatorcontrib><creatorcontrib>Rhee, Jinnie</creatorcontrib><collection>Web of Knowledge</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science - Social Sciences Citation Index – 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Social Sciences Citation Index</collection><collection>Web of Science Primary (SCIE, SSCI & AHCI)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Proquest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC geriatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Joo-Hyun</au><au>Lee, Jessie</au><au>Yu, Su-Yeon</au><au>Jung, Jin-Hyung</au><au>Han, Kyungdo</au><au>Kim, Do-Hoon</au><au>Rhee, Jinnie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease</atitle><jtitle>BMC geriatrics</jtitle><stitle>BMC GERIATR</stitle><addtitle>BMC Geriatr</addtitle><date>2020-10-15</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><spage>407</spage><epage>11</epage><pages>407-11</pages><artnum>407</artnum><issn>1471-2318</issn><eissn>1471-2318</eissn><abstract>Background Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI. Methods A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients >= 50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use. The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72). Results The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (Pfor trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32-1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26-1.50). Conclusions The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for >= 1 year and regularly in the recent 1 year.</abstract><cop>LONDON</cop><pub>Springer Nature</pub><pmid>33059626</pmid><doi>10.1186/s12877-020-01794-3</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-4358-4208</orcidid><orcidid>https://orcid.org/0000-0001-5488-5068</orcidid><orcidid>https://orcid.org/0000-0001-7421-4501</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2318 |
| ispartof | BMC geriatrics, 2020-10, Vol.20 (1), p.407-11, Article 407 |
| issn | 1471-2318 1471-2318 |
| language | eng |
| recordid | cdi_webofscience_primary_000582231800003CitationCount |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerNature Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Web of Science - Social Sciences Citation Index – 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Springer Nature OA/Free Journals |
| subjects | Age Aged Aged, 80 and over Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - adverse effects Bisphosphonates Body mass index Case-Control Studies Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Exercise Female Fracture Fractures Gastroesophageal reflux Gastroesophageal Reflux - drug therapy Gastroesophageal Reflux - epidemiology Gastroesophageal reflux disease Geriatrics Geriatrics & Gerontology Gerontology Histamine H2 Antagonists - administration & dosage Histamine H2 Antagonists - adverse effects Histamine H2 receptors Hormone replacement therapy Humans Life Sciences & Biomedicine Male Medical screening Older people Osteoporosis Osteoporotic Fractures - chemically induced Osteoporotic Fractures - epidemiology Peptic Ulcer - drug therapy Peptic Ulcer - epidemiology Peptic ulcer disease Peptic ulcers Physical fitness Population Surveillance Prescription drugs Proton pump inhibitors Proton Pump Inhibitors - administration & dosage Proton Pump Inhibitors - adverse effects Proton-pump inhibitor Republic of Korea - epidemiology Risk factors Science & Technology Sex ratio Treatment Outcome Ulcers |
| title | Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T20%3A58%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparing%20proton%20pump%20inhibitors%20with%20histamin-2%20receptor%20blockers%20regarding%20the%20risk%20of%20osteoporotic%20fractures:%20a%20nested%20case-control%20study%20of%20more%20than%20350,000%20Korean%20patients%20with%20GERD%20and%20peptic%20ulcer%20disease&rft.jtitle=BMC%20geriatrics&rft.au=Park,%20Joo-Hyun&rft.date=2020-10-15&rft.volume=20&rft.issue=1&rft.spage=407&rft.epage=11&rft.pages=407-11&rft.artnum=407&rft.issn=1471-2318&rft.eissn=1471-2318&rft_id=info:doi/10.1186/s12877-020-01794-3&rft_dat=%3Cproquest_webof%3E2451835720%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451835720&rft_id=info:pmid/33059626&rft_doaj_id=oai_doaj_org_article_266d4d43e509415380a1dbe7673811db&rfr_iscdi=true |